

9. (Amended) Method according to claim 1 wherein the treatment or prevention comprises administration of a dosage unit of EPO and/or an EPO equivalent.

10. (Amended) Method according to claim 1 wherein a combination of α -MSH and/or α -MSH equivalent with EPO and/or an EPO equivalent is administered.

Please cancel claim 11.

Please add the following claims:

13. (New) Method according to claim 3 wherein the dosage of α -MSH and/or of an α -MSH equivalent and EPO and/or an EPO equivalent is administered as a single dosage, regular or continued administration, or as a sequential administration.

14. (New) Method according to claim 3 wherein condition is caused by an infection.

15. (New) Method according to claim 3 wherein the condition is caused by a cancer or a by premalignant disorder.

16. (New) Method according to claim 3 wherein the α -MSH equivalent is a substance acting on the α -MSH receptor and/or on the melanocortin receptor.

17. (New) Method according to claim 3 wherein the treatment or prevention comprises administration of a dosage unit of EPO and/or an EPO equivalent.

18. (New) Method according to claim 3 wherein a combination of α -MSH and/or α -MSH equivalent with EPO and/or an EPO equivalent is administered.

If, inadvertently, a proper multiple dependent claim has not been amended to reduce it to single dependency, please amend it to be dependent solely on the first-mentioned claim, or, if that is not possible, please cancel the claim and notify the undersigned.